SCHEMBL4858207

SCHEMBL4858207

CCc1cnc(C#Cc2ccccc2)nc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 7/20 0.45
APP P05067 1/20 0.44
FFAR1 O14842 3/20 0.42
FFAR4 Q5NUL3 1/20 0.42
TP53 P04637 2/20 0.41
CHRNB2 P17787 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA7 P36544 1/20 0.38
CHRNA4 P43681 1/20 0.38
ADORA2A P29274 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4862760 0.98 GRM5 (0.44) GRM5APPFFAR1FFAR4TP53
SCHEMBL9495560 0.81 ACACB (0.41) FFAR1
SCHEMBL9496054 0.78 MCHR1 (0.50)
SCHEMBL9500956 0.78 MCHR1 (0.50) KDM4ENPC1ALDH1A1CYP1A2CYP3A4
SCHEMBL9499310 0.78 ALDH1A1 (0.42) FFAR1FFAR4TP53KDM4EMEN1
SCHEMBL9495311 0.77 HSD17B10 (0.45) FFAR1FFAR4TP53ADORA2AKDM4E
SCHEMBL9713096 0.76 ACACB (0.45) FFAR1MEN1ALDH1A1KMT2AGRIN2B
SCHEMBL9495406 0.76 HSD17B10 (0.48) FFAR1FFAR4TP53ADORA2AKDM4E
SCHEMBL9496159 0.76 MCHR1 (0.48) TP53KDM4ENPC1ALDH1A1CYP1A2
SCHEMBL2831073 0.76 TP53 (0.59) APPFFAR1FFAR4TP53CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462619-B2 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK & CO., INC. (US) 2008-12-09 US disclosed
US-7365074-B2 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK & CO., INC. (US) 2008-04-29 US disclosed
US-20050245542-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK SHARP & DOHME CORP. 2005-11-03 US disclosed
US-20050085523-A1 Imidazolyl and pyrazolyl ethyne compounds COSFORD NICHOLAS D (US) 2005-04-21 US disclosed
US-20050043307-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds MERCK SHARP & DOHME CORP. 2005-02-24 US disclosed
US-6774138-B2 TO FUNCTION AS AGONISTS OR ANTAGONISTS OF RECEPTORS FOR NEUROTRANSMITTERS, NEUROHORMONES AND NEUROMODULATORS, AS INSECTICIDES AND FINGICIDES MERCK & CO., INC. 2004-08-10 US disclosed
US-20030055247-A1 Thiazolyl(pyridyl)ethyne compounds MERCK SHARP & DOHME CORP. 2003-03-20 US disclosed
EP-1214303-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Merck & Co., Inc. (US) 2002-06-19 EP disclosed
WO-2001016121-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF MERCK & CO., INC. (US) 2001-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055247-A1 Thiazolyl(pyridyl)ethyne compounds CBR3, CBR1, CHRM3 GRM5 54/4885APP 2663/4885FFAR1 730/4885
US-20050043307-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds CBR3, P2RX5, CBR1 GRM5 45/4885APP 2114/4885FFAR1 898/4885
US-20050085523-A1 Imidazolyl and pyrazolyl ethyne compounds CBR3, CBR1, CHRM3 GRM5 67/4885APP 3160/4885FFAR1 547/4885
US-20050245542-A1 Pyridazine, pyrimidine and pyrazine ethyne compounds P2RX5, P2RY12, P2RY4 GRM5 52/4885APP 2144/4885FFAR1 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.